Penserra Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Penserra Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-48,749	Closed	-$3.02M	–	1241
2023 Q4	$3.02M	Buy	+48,749	New	+$2.56M	0.06%	221
2023 Q3	–	Sell	-64,291	Closed	-$3.69M	–	1242
2023 Q2	$3.69M	Buy	+64,291	New	+$2.85M	0.07%	186
2022 Q2	–	Sell	-178,801	Closed	-$6.42M	–	1381
2022 Q1	$6.42M	Buy	+178,801	New	+$5.07M	0.15%	163
2021 Q4	–	Sell	-1,100	Closed	-$20K	–	1361
2021 Q3	$20K	Buy	1,100 +15	+1%	+$294	﹤0.01%	1243
2021 Q2	$21K	Buy	1,085 +15	+1%	+$283	﹤0.01%	1131
2021 Q1	$19K	Sell	1,070 -20	-2%	-$372	﹤0.01%	975
2020 Q4	$21K	Buy	1,090 +686	+170%	+$13.3K	﹤0.01%	842
2020 Q3	$7K	Buy	+404	New	+$8.13K	﹤0.01%	846

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Penserra Capital Management's AMPH Position: Q1 2024 in Review

Penserra Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 48,749 shares — an estimated $3.02M sold.

Penserra Capital Management first reported a position in AMPH in Q3 2020 and held it in 8 quarters. The position peaked at $6.42M in Q1 2022. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

Penserra Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Penserra Capital Management sold 48,749 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $3.02M.
Penserra Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Penserra Capital Management's Amphastar Pharmaceuticals position peaked at $6.42M in Q1 2022.
270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Penserra Capital Management's 13F filing for Q1 2024, filed 15 May 2024.